-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – camsirubicin
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry camsirubicin Drug Details camsirubicin is under development for the treatment of advanced soft tissue...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – clonidine ER
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry clonidine ER Drug Details Clonidine ER (Validive, BA-028) is under development for the prevention...
-
Product Insights
Pancreatic Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer – Drugs In Development, 2022, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood...
-
Product Insights
COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2021
COVID-19 enzyme immuno assay/enzyme linked immunosorbent assay (EIA/ELISA) is the most widely used assays having high sensitivity and specificity. They are used to detect the recombinant protein and peptide antigens in the samples. The COVID-19 EIA/ELISA pipeline product report provides comprehensive information about the pipeline products with comparative analysis at various stages of development and information about the clinical trials which are in progress. The report also provides key information and clinical trial data regarding ongoing clinical trials such as...
-
Product Insights
COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) – Medical Devices Pipeline Assessment, 2020
COVID 19 EIA/ELISA are the most widely used assays having high sensitivity and specificity. They are used to detect the recombinant protein and peptide antigens in the samples. ELISA’s are specifically designed to screen large number of samples at a time. GlobalData's Medical Devices sector report, “COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) -Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) pipeline products with comparative analysis of...
-
Sector Analysis
PharmaFocus: Supportive Care in Oncology
Supportive care in oncology is a broad term that is composed of indications that are either a symptom of a patient’s cancer or a side effect of cancer treatment. This report focuses on six prominent cancer supportive care indications: chemotherapy-induced nausea and vomiting (CINV), cancer cachexia, oral mucositis, bone metastases, chemotherapy-induced neutropenia (CIN), and chemotherapy-induced anemia (CIA). There is a consensus among KOLs across the 7MM that supportive oncology had not been given much priority by physicians and institutions in...